Placing of £1,000,000

Summary by AI BETAClose X

CRISM Therapeutics Corporation has successfully raised £1,000,000 through an oversubscribed placing of 11,111,112 new ordinary shares at 9 pence per share, with each share receiving a warrant exercisable at 15 pence. The net proceeds will fund the company's MHRA-approved Phase 2 clinical trial of irinotecan-ChemoSeed for glioblastoma, covering sterilisation, quality control, clinical trial costs, and operational expenses, with first patient dosing anticipated in Q1 2026. A separate retail offer to raise up to £100,000 is also planned. Directors participated in the placing, acquiring shares and warrants, which has been deemed fair and reasonable by the company's nominated adviser.

Disclaimer*

UK 100

Latest directors dealings